Aquinox Pharmaceuticals Inc. (AQXP) announced Wednesday morning that its Phase 3 clinical trial of once-daily, oral rosiptor, for the treatment of interstitial cystitis/bladder pain syndrome, failed to meet its primary endpoint.
from RTT - Before the Bell https://ift.tt/2IxCmVZ
via IFTTT
No comments:
Post a Comment